2024-03-13 13:11:39 ET
Summary
- The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis.
- Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation.
- Voyager’s investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.
In this article, I will be providing a financial and scientific analysis of Voyager Therapeutics Inc. ( VYGR ). Financially speaking, Voyager is still due to live up to its expectations, which might be one of the reasons for their common stock share price volatility: losing -7.5% between February 28th, 2024 (earnings release day) and February 29th, 2024, bouncing back up 15.87% until March 4th, when they started to trend down again, with the share price standing at USD 9.23 at the moment of writing this article....
Read the full article on Seeking Alpha
For further details see:
Voyager Therapeutics: On Track To Deliver High Returns On Investment